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Abstract
The aim of the present study was to investigate the rs1800468 (G-800A), rs1800469 (C-509T), rs1800470 (C29T), and rs1800471 (G74C) TGFB1 
genetic polymorphisms and their haplotype structures in patients with Wilms Tumor (WT) and neoplasia-free controls. The genomic DNA was 
extracted from 35 WT patients and 160 neoplasia-free children, and the TGFB1 polymorphisms were genotyped by polymerase chain reaction, 
followed by restriction fragment length polymorphism. The haplotype structures were inferred, and permutation and logistic regression tests 
were performed to check for differences in haplotype distribution between the control and WT individuals. Positive associations were found in 
the recessive model for rs1800469 T allele (OR: 8.417; 95% CI: 3.177 to 22.297; P < 0.001) and for the rs1800470 C allele (OR: 3.000; 95% CI: 
1.296 to 6.944; P = 0.01). Haplotype analysis revealed a significant negative association between GCTG and WT (OR: 0.236, 95% CI: 0.105 
to 0.534; P = 0.0002); by contrast, the GTTG haplotype was associated with increased risk for WT (OR: 12.0; 95% CI: 4.202 to 34.270; P < 
0.001). Furthermore, rs1800469 was negatively correlated with tumor size and a trend toward a positive correlation for capsular invasion was 
observed in the dominant model (Tau-b: −0.43, P = 0.02 and tau-b: 0.5, P = 0.06, respectively). This is the first study with rs1800468, rs1800469, 
rs1800470, and rs1800471 TGFB1 polymorphisms in WT, and our results suggest that the TGFB1 promoter and signal peptide region polymor-
phisms may be associated with WT susceptibility and clinical presentation.
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Introduction
Wilms tumor (WT), or nephroblastoma, is a childhood kid-
ney cancer originated from the pluripotent embryonic kidney 
precursor (1) and consists histologically of smooth stromal, 
epithelial, and undifferentiated mesenchymal cells (2). It is 
the most common pediatric kidney tumor, affecting 1:10,000 
children (3).
The incidence of this disease is increased in low-income 
countries, which also present the lowest survival rates for this 
disease. Therefore, there is a need for accurate and compre-
hensive records for the appropriate allocation of resources 
in order to improve the outcome for this curable childhood 
malignancy (4).
The survival rate in patients has increased considerably in 
recent decades to more than about 90% for localized disease 
and to over 70% for metastatic disease (5). However, despite 
a good response to therapy and high success rates, there are 
concerns due to the risk of irreparable side effects  (6), as 
it targets cells with a high proliferative rate and the tumor 
affects tissues still in development (7). Furthermore, the 
prognostic indicators of recurrence and mortality are the 
disease stage and tumor histology, and the most significant 
unfavorable factors are the advanced stage and the presence 
of anaplasia, especially in the diffuse form, which is highly 
resistant to chemotherapy (8). Thus, improving our knowl-
edge of tumor biology and biomarker identification may help 
to promote risk stratification and to introduce new targeted 
therapies that could minimize toxicity and enhance out-
comes for patients with WT with unfavorable prognosis (6).
The tumor microenvironment is dynamic and its inter-
action with tumor cells is essential for cancer development, 
influencing growth, invasiveness, and metastatic process (9). 
In this context, transforming growth factor beta 1 (TGFβ1) 
is a pleiotropic cytokine that plays an important role in 
embryogenesis (10) and in physiological and pathological 
contexts by interfering with the cell cycle, apoptosis, and 
differentiation, also playing important roles in carcinogenic 
processes (11).
In normal and preneoplastic cells, TGFβ1 acts as a 
tumor suppressor associated with antiproliferative activ-
ity and apoptosis, but in advanced cancer stages, it acts as 
a tumor progression mediator (12). In malignant cells and 
at advanced stages of carcinogenesis, TGFβ1 promotes cell 
growth and epithelial-mesenchymal transition (EMT), which 
increase the invasiveness of these cells. In addition, it acts in 
the extracellular matrix remodeling and in immune system 
cells, inducing immunosuppression by generating regulatory 
T cells, anergy, and effector T-cells senescence, and angiogen-
esis through endothelial and smooth muscle cell activation, 
which favor the metastatic process (11).
In addition, it has been demonstrated that TGFβ1 reg-
ulates WT 1 gene (WT1) expression (13), a transcription 
factor necessary for kidney (14), gonads, and adrenal glands 
development (15). Also, its expression was found in a wide 
range of adult tumor types, such as colorectal cancer (16), 
lung cancer (17), and leukemia (18, 19).
There are also challenging aspects in WT evaluation, in 
relation to current and future markers of biological behav-
ior with prognostic significance (20). Many polymorphisms 
have been reported in the TGFB1 gene (21) including 
rs1800468 (G-800A, c.-1638G>A, c.*18G>A) and rs1800469 
(C-509T, c.-1347T>C, c.*309T>C) in the promoter region 
and rs1800470 (c.29C>T, Leu10Pro, T869C) and rs1800471 
(c.74G>C, Arg25Pro) in the signal peptide region that have 
been the most widely studied due to their potential func-
tional implications on the dynamics of TGFβ1 expression 
and secretion. These polymorphisms have been associated 
with diverse cancers, including gastric cancer (22), esoph-
ageal squamous cell carcinoma (23), and breast cancer 
(BC) (24). Overall, results are controversial in the literature, 
varying according to cancer types and even among molecu-
lar subtypes and disease stage within tumor groups (24, 25). 
However, they have not yet been studied in WT pathogenesis.
Therefore, the aim of this study was to verify the genotype 
frequencies of TGFB1 rs1800468, 1800469, 1800470, and 
1800471, and their haplotype structures in WT patients and 
neoplasia-free controls in a Brazilian population.
Materials and Methods
Human subjects
The present study was approved by the Institutional Human 
Research Ethics Committee of Londrina State University, 
Paraná, Brazil (CAAE 73557317000005231). The form 
granting free and informed consent was signed by the par-
ents of all the children and adolescents, and we also obtained 
the consent of those patients with decision-making ability 
to participate in the project. The WT samples consisted of 
35 archived paraffin-embedded tumor tissues from child 
patients from the North of Paraná Laboratory of Anato-
mopathology and Cytology (Micropar) and the Laboratory 
of Pathology of the University Hospital of Londrina State 
University. Of these, 14 (40%) were males and 21 (60%) were 
females. Tumor staging distribution was 7 (29%), 6 (25%), 
4 (16.7%), 6 (25%), and 1 (4.2%) for stages I, II, III, IV, 
and V, respectively (information was missing for 11 patients). 
Patients’ age ranged from 1 to 13 years (median: 3).
The control group consisted of 160 samples from 
neoplasia- free healthy children or young adults, which 
included 124 blood samples and 36 buccal cell samples col-
lected in University Hospital of Londrina State University. 
Among the control group, 77 (48.1%) patients were male and 
83 (51.9%) were female, and the control group age ranged 
from 3 months to 19 years (median: 12).
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DNA extraction
DNA from the control group was obtained from peripheral 
white blood cells using a Mini Spin extraction kit (Biometrix, 
Curitiba, Brazil), following the manufacturer’s instructions, 
and, in some cases, the DNA was obtained from buccal cells 
using a protocol based on the use of ammonium acetate (26). 
In the WT group, genomic DNA was isolated from formalin- 
fixed, paraffin-embedded tissues using the innuPREP DNA 
Mini Kit (Analytik Jena AG, Jena, Germany), following the 
manufacturer’s instructions. All DNA samples were quanti-
fied by NanoDrop 2000® Spectrophotometer (NanoDrop 
Technologies, Wilmington, USA) at 260nm wavelength, and 
the absorbance ratio at 260/280nm was used to assess protein 
contamination in DNA samples.
Genetic polymorphisms genotyping
Genetic polymorphisms were analyzed by polymerase 
chain reaction (PCR), followed by Restriction Fragment 
Length Polymorphism (RFLP) analysis, as described by 
Jin et  al.  (27), with modifications. All PCR amplicons and 
restriction fragments were analyzed by electrophoresis in 
acrylamide gels (10%), detected by silver staining.
The TGFB1 regions encompassing polymorphisms (pro-
moter and signal peptide regions) were amplified using the 
same reaction condition, 4 ng/µL of DNA, 1 × high fidelity 
PCR buffer, 1 mM MgSO4, 0.2 μM primers, 0.13 mM dNTP, 
and 1 U PlatinumTM Taq DNA polymerase High Fidelity. All 
PCR reagents were purchased from Invitrogen TM (Carlsbad, 
CA, USA).
For the promoter region polymorphisms (rs1800468 and 
rs1800469), the primer sequences were 5’-GCAGTTGG-
CGAGAACAGTTG-3’ and 5’-CCAGAACGGAAGGA-
GAGTCAG-3’. The PCR conditions were 10 min at 94°C, 
35 cycles of 45 s at 94°C, 1 min at 59°C and 1 min and 15 s 
at 72°C, and 10 min at 72°C. For the rs1800468 genotype 
analysis, PCR products (597 bp) were subjected to enzy-
matic digestion by HpyCH4IV (New England Biolabs®, 
 Ipswich, USA) and the genotype profiles were GG (402 bp 
and 195  bp), GA (597 bp, 402 bp, and 195 bp), and AA 
(597 bp). For the rs1800469 genotype analysis, PCR prod-
ucts (597  bp) were subjected to digestion by Bsu36I (New 
England  Biolabs®) and the genotype profiles were CC (488 
bp and 109 bp), CT (597 bp, 488 bp, and 109 bp), and TT 
(597 bp).
Primer sequences for the signal peptide region (rs1800470 
and rs1800471) were: 5’-TTCCCTCGAGGCCCTCCTA-3’ 
and 5’-GCCGCAGCTTGGACAGGATC-3’ and PCR con-
ditions were 10 min at 96°C, 35 cycles of 75 s at 96°C, 75 s at 
62°C and 75 s at 73°C, and 5 min at 73°C. For the rs1800470 
polymorphism, PCR products (294 bp) were subjected to 
enzymatic digestion by MspA1I (New England Biolabs®) 
and the genotypes were CC (149 bp, 67 bp, 40 bp, 26 bp, and 
12 bp), CT (161 bp, 149 bp, 67 bp, 40 bp, and 26 bp), and TT 
(161 bp, 67 bp, 40 bp, and 26 bp). For the rs1800471 poly-
morphism, PCR products (294 bp) were subjected to enzy-
matic digestion by BglI (New England Biolabs®) and the 
genotype profiles were GG (131 bp, 103 bp, and 60 bp), GC 
(163 bp, 131 bp, 103 bp, and 60 bp), and CC (163 bp and 131 
bp) (Figure 1).
To confirm the primers’ specificity used in the present 
study, some PCR products for both TGFB1 regions were puri-
fied using the PureLink™ PCR Purification Kit  (Invitrogen, 
Cashland, USA) following the manufacturer’s instructions 
and sequenced. The sequencing reaction was performed 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems®, Foster City, USA). The amplicons 
were sequenced in a 24-capillary 3500×l Genetic Analyzer 
(Applied Biosystems®). The resulting sequences revealed 
identity with GenBank NG_013364.1 (TGFB1) confirming 
primer specificity for all polymorphisms.
Statistical analyses
The case-control study for WT susceptibility was performed 
by the Odds Ratio (OR) calculus, adopting an estimate 
of the relative risk at 95% confidence intervals (CI), and 
 Fisher’s exact test. Genotypic (variant homozygotes or het-
erozygotes versus wild homozygotes), dominant (variant 
homozygotes and heterozygotes versus wild homozygotes), 
and recessive (variant homozygotes versus heterozygotes 
and wild homozygotes) models were tested for all individual 
polymorphisms. Correlation analyses between the polymor-
phisms and WT clinicopathological features were assessed by 
the Kendall’s tau-b rank correlation coefficient. The TGFB1 
haplotypes were determined using PHASE software version 
2.1.1 (28) using all the study participants’ genotypes, and the 
software was used to perform permutation tests to check the 
difference among haplotype distributions between the con-
trol and WT individuals. All other statistical analyses were 
performed in IBM® SPSS® Statistics 24.0 software (IBM®, 
Armonk, New York, USA). All tests were two-tailed with a 
significance level set at 0.05.
Results
Case-control association studies were conducted to deter-
mine the possible influence of polymorphisms on WT sus-
ceptibility. The genotype frequencies and case-control 
analyses for the promoter region (rs1800468 and rs1800469) 
and signal peptide (rs1800470 and rs1800471) polymor-
phisms are shown in Tables 1 and 2, respectively. The gen-
otype frequencies for these polymorphisms in the control 
group were consistent with an independent control sample 
collected from the same geographical region (24).
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Figure 1: Promoter and signal peptide regions of TGFB1 genetic polymorphisms profile. Electrophoretic profile of: (A) rs1800468 
(G-800A), (B) rs1800469 (C-509T), (C) rs1800470 (c.29C>T), and (D) rs1800471 (c.74G>C). The PCR products after restric-
tion digestion were analyzed by electrophoresis on acrylamide gel (10%), detected by silver staining method. L: Ladder 100 bp; 
C: negative control.
For the TGFB1 promoter region polymorphisms, the 
case-control study indicated no significant association for 
the rs1800468 polymorphism. However, the rs1800469 poly-
morphism presented a positive association for the T allele in 
the recessive model (OR: 8.417; 95% CI: 3.177 to 22.297; P < 
0.001) (Table 1).
Similarly, when the TGFB1 signal peptide polymor-
phisms were analyzed, a significant association was found 
for the rs1800470 polymorphism with increased risk for WT 
in the recessive model (OR: 3.000; 95% CI: 1.296 to 6.944; 
P = 0.01). However, no significant association was found for 
the rs1800471 polymorphism (Table 2). For this polymor-
phism, analysis evaluating the CC genotype was not possible 
due to the absence of this genotype in the control group.
Correlation between polymorphisms and clinicopatholog-
ical features were analyzed considering additive, dominant, 
and recessive models. A negative correlation was observed 
between tumor size (≤8 cm vs >8 cm) and rs1800469 in the 
dominant model (Tau-b = −0.43; P = 0.02; Table 3). Further-
more, the lack of statistical significance in the positive cor-
relation between this model and capsular invasion was only 
marginal (Tau-b = 0.5; P = 0.06; Table 3). No other signifi-
cant correlation was observed for any variant analyzed.
Twenty-two WT samples that could be genotyped for the 
four polymorphisms were included for haplotype analysis. 
Nine possible inferred haplotypes were observed (Table 4). 
A significant difference among the controls and patients 
with WT was observed (P = 0.001) in global haplotype dis-
tribution (Table 4). Based on these results, a case-control 
study of the association of individual haplotype structures 
indicated that the GCTG haplotype conferred protection 
against tumor development (OR: 0.236; 95% CI: 0.105 to 
0.534; P = 0.0002) and GTTG was associated with risk (OR: 
12.000; 95% CI: 4.202 to 34.270; P < 0.0001) (Table 4). For 
this analysis, each haplotype structure was compared to the 
total number of haplotypes in the group, and the ACCC and 
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Table 1: Genotypic frequencies in WT and control patients and case-control study for TGFB1 promoter region polymorphisms 
(rs1800468 and rs1800469).
Models Controls [n (%)] Patients [n (%)] Odds ratio 95% CI P value
rs1800468
GG 105 (92.1) 26 (92.8) Reference – –
GA 7 (6.1) 1 (3.6) 0.577 0.068–4.898 0.577
AA 2 (1.8) 1 (3.6) 2.019 0.176–23.133 0.572
Dominant model
GG 105 (92.1) 26 (92.8) Reference – –
AA+GA 9 (7.9) 2 (7.2) 0.897 0.183–4.406 0.894
Recessive model
GG+GA 112 (98.2) 27 (96.4) Reference – –
AA 2 (1.8) 1 (3.6) 2.074 0.181–23.724 0.557
rs1800469
CC 43 (37.7) 6 (24.0) Reference – –
CT 58 (50.9) 6 (24.0) 0.741 0.224–2.457 0.625
TT 13 (11.4) 13 (52.0) 7.167 2.271–22.615 <0.001*
Dominant model
CC 43 (37.7) 6 (24.0) Reference – –
TT+CT 71 (62.3) 19 (76.0) 1.918 0.711–5.176 0.199
Recessive model
CC+CT 101 (88.6) 12 (48.0) Reference – –
TT 13 (11.4) 13 (52.0) 8.417 3.177–22.297 <0.001*
CI: confidence interval. Fisher’s exact test. *Significant (P < 0.05).
ATCG haplotype structures were not considered due to their 
absence in the control group.
Discussion
WT is a neoplasm of embryonic origin whose structures 
and composition recapitulate characteristics of normal 
nephrogenesis (29). Failures during embryogenesis are con-
sidered as the causes of WT (1). In this context, studies 
have demonstrated the crucial role of the TGFβ1 in meta-
nephric development during the fetal period (10), as well as 
in immunomodulation by inhibiting the activity of essen-
tial immune cells for the antitumor response. Thus, it is 
reasonable to assume that TGFβ1 also participates in WT 
development (30).
In the present study, we investigated four polymorphisms 
in TGFB1, two in the promoter region (rs1800468 and 
rs1800469) and two in the signal peptide region (rs1800470 
and rs1800471), that are somehow involved in expression 
regulation and secretion of this cytokine, in relation to WT 
susceptibility.
Despite numerous studies describing a role for TGFβ1 
in various neoplasms (22, 31), only two have demonstrated 
the direct participation of this cytokine in WT, associating 
TGFβ1 expression in tumor microenvironment invasion 
and disease progression (32), and showing that TGFβ1 
signaling is the most important coordinator of anaplastic 
histology  (33). However, studies on WT and genetic poly-
morphisms are even more scarce, and this is the first study 
evidencing these TGFB1 polymorphisms in this disease.
Genetic polymorphisms of the TGFB1 in Wilms tumor
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Table 2: Genotypic frequencies in WT and control patients and case-control study for TGFB1 signal peptide region 
polymorphisms (rs1800470 and rs1800471).
Models Controls [n (%)] Patients [n (%)] Odds ratio 95% CI P value
rs1800470
TT 24 (16.7) 12 (37.5) Reference – –
TC 83 (57.6) 11 (34.4) 0.545 0.208–1.426 0.216
CC 37 (25.7) 9 (28.1) 2.056 0.752–5.618 0.160
Dominant model
TT 24 (16.7) 12 (37.5) Reference – –
CC+TC 120 (83.3) 20 (62.5) 0.884 0.375–2.081 0.777
Recessive model
TT+TC 107 (74.3) 23 (71.9) Reference – –
CC 37 (25.7) 9 (28.1) 3.000 1.296–6.944 0.01*
rs1800471
GG 130 (90.3) 26 (81.2) Reference – –
GC 14 (9.7) 3 (9.4) 1.071 0.287–3.995 0.918
CC – 3 (9.4) NA NA NA
Dominant model
GG 130 (90.3) 26 (81.2) Reference – –
CC+GC 14 (9.7) 6 (18.8) 2.143 0.754–6.093 0.153
CI: confidence interval; Fisher’s exact test; *Significant (P < 0.05); NA: not available.
In this study, no association was found for the rs1800468 
polymorphism of the TGFB1 promoter region. Although no 
studies have evaluated this polymorphism in WT, some stud-
ies on other tumors have demonstrated increased risk asso-
ciated with the A allele, such as BC (34) and uterine cervical 
cancer (35), while others failed to observe any significant 
association (24, 27).
Nevertheless, when the rs1800469 TGFB1 polymorphism 
was analyzed, the T allele was associated with WT suscepti-
bility in the recessive model. While Jin, Deng (23), in a study 
on esophageal squamous cell carcinoma, have found asso-
ciation of the same variant with protection against cancer, 
studies on BC (24, 34) differently have shown an association 
of rs1800469 T allele with the risk of cancer.
The TGFB1 rs1800469 polymorphism is located in a Yin 
Yang 1 (YY1) transcription factor consensus-binding site. 
Studies using transient transfection analysis with promoter–
reporter constructs showed that the exchange from C to T 
at the −509 position of the promoter region could increase 
affinity for YY1 (36). This may be one of the mechanisms 
that leads to increased cytokine secretion in cancer patients’ 
plasma, as observed in cases of pancreatic cancer (31), gas-
tric cancer (22), as well as in cases of WT with poor progno-
sis (32).
For the signal peptide region, it was verified that the 
rs1800470 C allele was associated with WT development, in a 
recessive model. Similar results were found for other tumors, 
in which homozygous CC was associated with BC (37) and 
colorectal cancer (38) susceptibility.
Significant effect of rs1800470 polymorphism on the 
TGFβ1 secretion may provide an explanation for the 
reported associations with a variety of diseases, such as 
that of the present study. This polymorphism results in the 
exchange of a leucine (T) for a proline (C) at signal peptide 
amino acid 10, and it has been reported previously that the 
amount of TGFβ1 in serum is higher for CC homozygotes 
than TT homozygotes (39). Dunning, Ellis et al. (37), in a 
transfection study of HeLa cells with constructs encoding 
either the C or T allele of TGFB1, indicated that the sig-
nal peptide with the C allele causes a 2.8-fold increase in 
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Table 3: Correlation analyses between TGFB1 rs1800469 and WT patient’s clinicopathological features.
Parameter C-509T genotypes [n (%)] Models (Tau-b; P)
CC CT TT Additive Dominant Recessive
Tumor size
≤8 cm 0 (0.0) 3 (60.0) 2 (40.0) −0.12; 0.61 −0.43; 0.02* 0.09; 0.71
>8 cm 4 (40.0) 1 (10.0) 5 (50.0)
Capsular invasion
Absent 3 (60.0) 0 (0.0) 2 (40.0) 0.405; 0.13 0.50; 0.06 0.35; 0.20
Present 1 (12.5) 1 (12.5) 6 (75.0)
Nodal involvement
Absent 3 (37.5) 1 (12.5) 4 (50.0) −0.07; 0.77 0.04; 0.87 −0.17; 0.52
Present 2 (33.3) 2 (33.3) 2 (33.3)
Distant metastasis
Absent 1 (33.3) 1 (33.3) 1 (33.3) 0.00; 1.00 0.00; 1.00 0.00; 1.00
Present 2 (33.3) 2 (33.3) 2 (33.3)
*Significant (P < 0.05).
Table 4: Case-control association study for haplotype structures.
Haplotype structure Control [n (%)] WT [n (%)] Odds ratio (CI) P value
ACCC 0 (0.0) 1 (2.3) NA –
ACTG 10 (5.0) 1 (2.3) 0.437 (0.055–3.509) 0.694
ATCG 0 (0.0) 1 (2.3) NA –
GCCC 7 (3.5) 2 (4.6) 1.049 (0.212–5.206) 1.000
GCCG 14 (7.1) 2 (4.6) 0.506 (0.111–2.297) 0.534
GCTG 96 (48.5) 8 (18.2) 0.236 (0.105–0.534) <0.001*
GTCC 3 (1.5) 1 (2.3) 1.512 (0.153–14.890) 0.554
GTCG 62 (31.3) 16 (36.4) 1.253 (0.635–2.484) 0.593
GTTG 6 (3.0) 12 (27.3) 12.000 (4.202–34.270) <0.001*
Permutation P-value <0.001* – –
CI: confidence interval. NA: not analyzed. *Significant (P < 0.05) through permutation analysis (for global haplotype distribution) or Fisher’s 
exact test (for odds ratio).
secretion compared with the T allele form. This may reflect 
structure and property changes in the TGFβ1 signal peptide 
due to the substitution of amino acids.
Susianti, Handono (40) showed that the presence of pro-
line amino acid (allele C) changes the hydrophobic core 
region of the TGFβ1 signal peptide and breaks the α-helix 
structure favored by leucine (allele T), altering the stability 
of the signal peptide interaction with the Signal Recognition 
Particle (SRP) and translocation complex in endoplasmic 
reticulum, reducing the values on transmembrane tendency, 
and stabilizing protein partner binding. As the sequence 
of the signal peptide is responsible for allowing the export 
of new proteins to endoplasmic reticulum lumen and then 
secretion, such changes could modify the exportation 
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Few studies have performed a haplotype analysis of 
TGFB1 polymorphisms. Jin, Hemminki (27) conducted an 
analysis with the same four TGFB1 polymorphisms (pro-
moter and signal peptide regions) but no associations with 
BC were found; on the other hand, our group has showed 
subtype-specific associations between TGFB1 haplotypes 
and BC risk (24). Berndt et al. (38), in a study with five 
TGFB1 polymorphisms (rs1800468, rs1800469, rs1800470, 
rs1800471, and rs1800472), found an association of the 
GTCGC haplotype structure with susceptibility to colorec-
tal adenoma, which is partially compatible with our individ-
ual polymorphism analysis, where the T allele of rs1800469 
(C-509T) and C allele of rs1800470 (T869C) polymorphism 
conferred risk for WT.
Conclusion
This is the first study with the rs1800468, rs1800469, 
rs1800470, and rs1800471 TGFB1 polymorphisms in WT 
patients, and our results suggest that the rs1800469 and 
rs1800470 polymorphisms may serve as markers associ-
ated with the susceptibility and clinical presentation of this 
disease.
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